TY - JOUR
T1 - Effects of adaptive servoventilation therapy for central sleep apnea on health care utilization and mortality
T2 - A population-based study
AU - Mansukhani, Meghna P.
AU - Kolla, Bhanu Prakash
AU - Naessens, James M.
AU - Gay, Peter C.
AU - Morgenthaler, Timothy I.
N1 - Funding Information:
Work for this study was performed at Mayo Clinic, Rochester, MN. All authors have seen and approved the manuscript. This study was funded by ResMed Foundation. The authors of this study were involved in the design, conduct and analysis of the study and had full access to the data. ResMed Corp. did not have access to the data and did not perform any of the statistical analyses. MPM is the Principal Investigator of a research grant sponsored by the Paul and Ruby Tsai and Family Fund Career Development Award at Mayo Clinic, Rochester, Minnesota. The remaining authors report no conflicts of interest. No off-label or investigational product use is discussed in this manuscript. Parts of the results of this study were presented at SLEEP 2017 and SLEEP 2018 (APSS) meetings and appear in the corresponding abstract supplement issues of the journal Sleep published by the Sleep Research Society.
Publisher Copyright:
© 2019 American Academy of Sleep Medicine.All Rights Reserved.
PY - 2019/1/15
Y1 - 2019/1/15
N2 - Study Objectives: Adaptive servoventilation (ASV) is the suggested treatment for many forms of central sleep apnea (CSA). We aimed to evaluate the impact of treating CSA with ASV on health care utilization. Methods: In this population-based study using the Rochester Epidemiology Project database, we identified patients over a 9-year period who were diagnosed with CSA (n = 1,237), commenced ASV therapy, and had ≥ 1 month of clinical data before and after ASV initiation. The rates of hospitalizations, emergency department visits (EDV), outpatient visits (OPV) and medications prescribed per year (mean ± standard deviation) in the 2 years pre-ASV and post-ASV initiation were compared. Results: We found 309 patients (68.0 ± 14.6 years, 80.3% male, apnea-hypopnea index 41.6 ± 26.5 events/h, 78% with cardiovascular comorbidities, 34% with heart failure) who met inclusion criteria; 65% used ASV ≥ 4 h/night on ≥ 70% nights in their first month. The overall 2-year mortality rate was 9.4% and CSA secondary to cardiac cause was a significant risk factor for mortality (hazard ratio 1.81, 95% CI 1.09–3.01, P = .02). Comparing pre-ASV and post-ASV initiation, there was no change in the rate of hospitalization (0.72 ± 1.63 versus 0.79 ± 1.44, P = .46), EDV (1.19 ± 2.18 versus 1.26 ± 2.08, P = .54), OPV (31.59 ± 112.42 versus 13.60 ± 17.36, P = .22), or number of prescribed medications (6.68 ± 2.0 versus 5.31 ± 5.86, P = .06). No differences in these outcomes emerged after accounting for adherence to ASV, CSA subtype and comorbidities via multiple regression analysis (all P > .05). Conclusions: Our cohort of patients with CSA was quite ill and the use of ASV was not associated with a change in health care utilization.
AB - Study Objectives: Adaptive servoventilation (ASV) is the suggested treatment for many forms of central sleep apnea (CSA). We aimed to evaluate the impact of treating CSA with ASV on health care utilization. Methods: In this population-based study using the Rochester Epidemiology Project database, we identified patients over a 9-year period who were diagnosed with CSA (n = 1,237), commenced ASV therapy, and had ≥ 1 month of clinical data before and after ASV initiation. The rates of hospitalizations, emergency department visits (EDV), outpatient visits (OPV) and medications prescribed per year (mean ± standard deviation) in the 2 years pre-ASV and post-ASV initiation were compared. Results: We found 309 patients (68.0 ± 14.6 years, 80.3% male, apnea-hypopnea index 41.6 ± 26.5 events/h, 78% with cardiovascular comorbidities, 34% with heart failure) who met inclusion criteria; 65% used ASV ≥ 4 h/night on ≥ 70% nights in their first month. The overall 2-year mortality rate was 9.4% and CSA secondary to cardiac cause was a significant risk factor for mortality (hazard ratio 1.81, 95% CI 1.09–3.01, P = .02). Comparing pre-ASV and post-ASV initiation, there was no change in the rate of hospitalization (0.72 ± 1.63 versus 0.79 ± 1.44, P = .46), EDV (1.19 ± 2.18 versus 1.26 ± 2.08, P = .54), OPV (31.59 ± 112.42 versus 13.60 ± 17.36, P = .22), or number of prescribed medications (6.68 ± 2.0 versus 5.31 ± 5.86, P = .06). No differences in these outcomes emerged after accounting for adherence to ASV, CSA subtype and comorbidities via multiple regression analysis (all P > .05). Conclusions: Our cohort of patients with CSA was quite ill and the use of ASV was not associated with a change in health care utilization.
KW - Automatic servoventilation
KW - Complex sleep apnea
KW - Emergency room
KW - Hospitalization
KW - Mortality
KW - Outpatient visits
KW - Treatment-emergent central sleep apnea
UR - http://www.scopus.com/inward/record.url?scp=85060218588&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85060218588&partnerID=8YFLogxK
U2 - 10.5664/jcsm.7584
DO - 10.5664/jcsm.7584
M3 - Article
C2 - 30621843
AN - SCOPUS:85060218588
SN - 1550-9389
VL - 15
SP - 119
EP - 128
JO - Journal of Clinical Sleep Medicine
JF - Journal of Clinical Sleep Medicine
IS - 1
ER -